Curaleaf Holdings Inc banner

Curaleaf Holdings Inc
TSX:CURA

Watchlist Manager
Curaleaf Holdings Inc Logo
Curaleaf Holdings Inc
TSX:CURA
Watchlist
Price: 4 CAD -23.66% Market Closed
Market Cap: CA$3.1B

EV/OCF

21.6
Current
19%
Cheaper
vs 3-y average of 26.7

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
21.6
=
Enterprise Value
CA$3.7B
/
Operating Cash Flow
$137.7m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
21.6
=
Enterprise Value
CA$3.7B
/
Operating Cash Flow
$137.7m

Valuation Scenarios

Curaleaf Holdings Inc is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (26.7), the stock would be worth CA$4.95 (24% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-33%
Maximum Upside
+24%
Average Downside
2%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 21.6 CA$4
0%
3-Year Average 26.7 CA$4.95
+24%
5-Year Average 26.7 CA$4.95
+24%
Industry Average 14.4 CA$2.67
-33%
Country Average 16.7 CA$3.09
-23%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
US
Curaleaf Holdings Inc
TSX:CURA
3.1B CAD 21.6 -9.6
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 51.6 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 23.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15.2 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.1 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.2 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 18.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.5 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 17.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 10.6 16.8
P/E Multiple
Earnings Growth PEG
US
Curaleaf Holdings Inc
TSX:CURA
Average P/E: 21.9
Negative Multiple: -9.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

In line with most companies in the United States of America
Percentile
65th
Based on 9 518 companies
65th percentile
21.6
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Curaleaf Holdings Inc
Glance View

Curaleaf Holdings Inc., a prominent player in the burgeoning cannabis market, has carved out a significant niche for itself by fully integrating its operations from cultivation to distribution. Founded in 2010, the Massachusetts-based company has rapidly grown to become one of the largest cannabis retailers in the United States. With a keen eye on the complex regulatory landscape, Curaleaf has strategically expanded its footprint across multiple states, adapting to various state laws and regulations. Their operational strategy hinges on vertical integration, meaning they control every stage of the cannabis supply chain. This allows Curaleaf not only to maintain high product quality and consistency but also to maximize margins by reducing costs and gaining efficiencies at all levels of production and retailing. Generating revenue through a combination of wholesale and retail sales, Curaleaf has established a range of products including cannabis flower, oils, edibles, and topical treatments, catering to both medical and recreational customers. The company's retail outlets, spanning across multiple states, are crucial in driving sales, where knowledgeable staff guide customers through intricate product offerings aimed at satisfying diverse consumer needs. Meanwhile, Curaleaf’s wholesale division supplies products to other retail outlets, expanding its market reach and solidifying its brand presence. The synergy between its retail prowess and wholesale operations has allowed Curaleaf to sustain steady revenue growth, positioning it well in a highly competitive and rapidly evolving industry.

CURA Intrinsic Value
2.74 CAD
Overvaluation 31%
Intrinsic Value
Price CA$4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett